{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:24:42Z","timestamp":1793568282999,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006103.pub7","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000}}],"reference-count":477,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006103.pub8","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T20:58:30Z","timestamp":1683233910000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Nicotine receptor partial agonists for smoking cessation"],"prefix":"10.1002","volume":"2023","author":[{"given":"Jonathan","family":"Livingstone-Banks","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R","family":"Fanshawe","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla H","family":"Thomas","sequence":"additional","affiliation":[{"name":"School of Social and Community Medicine; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Theodoulou","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisa","family":"Hajizadeh","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Hartman","sequence":"additional","affiliation":[{"name":"University of Oxford Medical School; John Radcliffe Hospital; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lindson","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-159-6-201309170-00005","article-title":"Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial","volume":"159","author":"Anthenelli","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ntr\/nty033","article-title":"Effects of varenicline, depressive symptoms, and region of enrollment on smoking cessation in depressed smokers","volume":"21","author":"Doran","year":"2018","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0003|cit3","unstructured":"Safety and efficacy of 12 weeks of varenicline for smoking cessation in smokers with depression clinicaltrials.gov\/ct2\/show\/NCT01078298"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugalcdep.2019.03.011","article-title":"Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV","volume":"200","author":"Ashare","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub8-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1037\/adb0000619","article-title":"Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV","volume":"35","author":"Ashare","year":"2021","journal-title":"Psychology of Addictive Behaviors"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"106638","DOI":"10.1016\/j.addbeh.2020.106638","article-title":"Medication adherence and rate of nicotine metabolism are associated with response to treatment with varenicline among smokers with HIV","volume":"112","author":"Bauer","year":"2021","journal-title":"Addictive Behaviors"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/09540121.2019.1703891","article-title":"Improved clinical outcomes among persons with HIV who quit smoking","volume":"32","author":"Lubitz","year":"2020","journal-title":"AIDS Care"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0008|cit8","unstructured":"A placebo controlled trial of varenicline for smoking among those with HIV\/AIDS ClinicalTrials.gov\/show\/NCT01710137"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"106151","DOI":"10.1016\/j.addbeh.2019.106151","article-title":"Correlates of varenicline adherence among smokers with HIV and its association with smoking cessation","volume":"102","author":"Quinn","year":"2020","journal-title":"Addictive Behaviors"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00213-020-05451-w","article-title":"The effect of varenicline on mood and cognition in smokers with HIV","volume":"237","author":"Thompson","year":"2020","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0011|cit11","first-page":"752","article-title":"Authors' reply [to JE Rose]","volume":"63","author":"Bobak","year":"2008","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0012|cit12","first-page":"752","article-title":"Authors' reply [to T Hillman]","volume":"63","author":"Bobak","year":"2008","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0013|cit13","first-page":"1","article-title":"Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised, open-label trial","volume":"1","author":"Bobak","year":"2008","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/thx.2008.096081","article-title":"The place of varenicline in smoking cessation treatment","volume":"63","author":"Aveyard","year":"2008","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0015|cit15","first-page":"752","article-title":"Clinically significant outcomes in smoking cessation","volume":"63","author":"Hillman","year":"2008","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0016|cit16","first-page":"751","article-title":"Pre-cessation varenicline treatment vs post-cessation NRT: an uneven playing field","volume":"63","author":"Rose","year":"2008","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2015.19284","article-title":"Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks","volume":"315","author":"Baker","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/ntr\/ntac068","article-title":"Time-varying mediation of pharmacological smoking cessation treatments on smoking lapse via craving, cessation fatigue, and negative mood","volume":"24","author":"Chakraborti","year":"2022","journal-title":"Nicotine & Tobacco Research"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.15288\/jsad.2020.81.426","article-title":"Searching for personalized medicine for binge drinking smokers: smoking cessation using varenicline, nicotine patch, or combination nicotine replacement therapy","volume":"81","author":"Kaye","year":"2020","journal-title":"Journal of Studies on Alcohol and Drugs"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0020|cit20","first-page":"247A","article-title":"Searching for personalized medicine for heavy drinking smokers: smoking cessation using varenicline, nicotine patch, or combination nicotine replacement therapy","volume":"43 Suppl 1","author":"Kaye","year":"2019","journal-title":"Alcoholism: Clinical and Experimental Research Conference: 42nd Annual Scientific Meeting of the Research Society on Alcoholism"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/add.15248","article-title":"Comparative effects of varenicline or combination nicotine replacement therapy versus patch monotherapy on candidate mediators of early abstinence in a smoking cessation attempt","volume":"116","author":"Kim","year":"2020","journal-title":"Addiction"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/ntr\/nty157","article-title":"Quitting failure and success with and without using medication: latent classes of abstinence and adherence to nicotine monotherapy, combination therapy, and varenicline","volume":"21","author":"McCarthy","year":"2019","journal-title":"Nicotine & Tobacco Research"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/ntr\/ntz070","article-title":"Anxiety sensitivity and distress tolerance in smokers: relations with tobacco dependence, withdrawal, and quitting success","volume":"22","author":"Schlam","year":"2020","journal-title":"Nicotine & Tobacco Research"},{"issue":"15","key":"10.1002\/14651858.CD006103.pub8-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.2021.15333","article-title":"Effects of combined varenicline with nicotine patch and of extended treatment duration on smoking cessation: a randomized clinical trial","volume":"326","author":"Baker","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0025|cit25","unstructured":"UW Quitting Using Intensive Treatment Study (QUITS) clinicaltrials.gov\/show\/NCT03176784"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12971-017-0116-0","article-title":"A comparison of the efficacy of varenicline and bupropion and an evaluation of the effect of the medications in the context of the smoking cessation programme","volume":"15","author":"Benli","year":"2017","journal-title":"Tobacco Induced Diseases"},{"issue":"100228","key":"10.1002\/14651858.CD006103.pub8-BIB0027|cit27","first-page":"1","article-title":"Extending varenicline preloading to 6 weeks facilitates smoking cessation: a single-site, randomised controlled trial: six-week varenicline preloading for smoking cessation","volume":"19","author":"Bohadana","year":"2020","journal-title":"eClinicalMedicine"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0028|cit28","first-page":"A2378","article-title":"Extended, 6 weeks, varenicline preloading: does it facilitate smoking reduction and cessation? a randomized double-blind, placebo-controlled study","volume":"199","author":"Izbicki","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine Conference: 2019 International Conference of the American Thoracic Society"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0029|cit29","unstructured":"Extended (6-Week) varenicline preloading: does it facilitate smoking reduction and cessation? https:\/\/clinicaltrials.gov\/show\/NCT02634281"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.clinthera.2011.04.013","article-title":"Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study","volume":"33","author":"Bolliger","year":"2011","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0031|cit31","first-page":"16 [O027]","article-title":"Cost effectiveness of an inpatient smoking cessation intervention for patients with tobacco related illnesses (Stop Trial): a multi-centre RCT [Abstract]","volume":"18 Suppl 2","author":"Brinn","year":"2013","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0032|cit32","first-page":"45","article-title":"Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 24-month randomised controlled trial for inpatients","volume":"21 Suppl 2","author":"Carson","year":"2016","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0033|cit33","first-page":"115","article-title":"Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: A 24-month randomized controlled trial for inpatients","volume":"20 Suppl 3","author":"Carson","year":"2015","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0034|cit34","first-page":"115","article-title":"Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 24-month randomized controlled trial for inpatients","volume":"20","author":"Carson","year":"2015","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0035|cit35","first-page":"A30","article-title":"Varenicline tartrate and counselling versus counselling alone in a randomised controlled trial for inpatient smoking cessation: 3 month interim results [Abstract]","volume":"15 Suppl 1","author":"Carson","year":"2010","journal-title":"Respirology"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/ntr\/ntu112","article-title":"Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: a randomized controlled trial for inpatients (STOP study)","volume":"16","author":"Carson","year":"2014","journal-title":"Nicotine & Tobacco Research"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"e0231095","DOI":"10.1371\/journal.pone.0231095","article-title":"Two-year efficacy of varenicline tartrate and counselling for inpatient smoking cessation (STOP study): a randomized controlled clinical trial","volume":"15","author":"Carson-Chahhoud","year":"2020","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0038|cit38","first-page":"40 [TO 076]","article-title":"Triggers resulting in relapse: cohort analysis from the smoking termination opportunity for inpatients (STOP) trial [Abstract]","volume":"19 Suppl 2","author":"Hnin","year":"2014","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0039|cit39","first-page":"PA4600","article-title":"Cost effectiveness of inpatient initiated varenicline tartrate (VT) plus counselling compared to counselling alone: 2 year follow-up of the Smoking Termination Opportunity for inPatients (STOP) study","volume":"48","author":"Smith","year":"2016","journal-title":"European respiratory journal. Conference: European Respiratory Society Annual Congress 2016. United Kingdom"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/thoraxjnl-2012-202484","article-title":"Smoking termination opportunity for in patients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients","volume":"68","author":"Smith","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Smith BJ Peters MJ Fitridge RA Esterman AJ Litt JC Horowitz JD Varenicline tartrate and counselling versus counselling alone in a randomised controlled trial for inpatient smoking cessation: 6 month interim results Conference: American Thoracic Society 2011 International Conference, May 13-18 2011","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A5445"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/cpt.1971","article-title":"Genetic variant in CHRNA5 and response to varenicline and combination nicotine replacement in a randomized placebo-controlled trial","volume":"108","author":"Chen","year":"2020","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0043|cit43","unstructured":"Genetically informed smoking cessation trial ClinicalTrials.gov\/show\/NCT02351167"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub8-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4088\/JCP.13m08756","article-title":"Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study","volume":"75","author":"Chengappa","year":"2014","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0045|cit45","first-page":"38","article-title":"A randomized, double-blind, placebo-controlled clinical trial of varenicline in persons with bipolar disorder motivated to quit smoking","volume":"17","author":"Chengappa","year":"2015","journal-title":"Bipolar Disorders"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JCP.0000000000000272","article-title":"An association between the use of hypnotics and quit status in the treatment of nicotine dependence with varenicline in bipolar disorder","volume":"35","author":"Forrest","year":"2015","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0047|cit47","unstructured":"Varenicline treatment for smoking cessation in patients with bipolar disorder (BEST) clinicaltrials.gov\/ct2\/show\/NCT01010204"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00213-017-4580-2","article-title":"Benefits of varenicline vs. bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment","volume":"234","author":"Cinciripini","year":"2017","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/eb-2013-101619","article-title":"Randomised controlled trial: study suggests varenicline safe and effective among adults with stable depression","volume":"19","author":"Cinciripini","year":"2014","journal-title":"Evidence-Based Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamapsychiatry.2013.678","article-title":"Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal","volume":"70","author":"Cinciripini","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpsycho.2017.12.001","article-title":"Pharmacological intervention and abstinence in smokers undergoing cessation treatment: a psychophysiological study","volume":"123","author":"Cui","year":"2018","journal-title":"International Journal of Psychophysiology"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/eb-2013-101435","article-title":"Varenicline may reduce negative effect while aiding smoking cessation","volume":"19","author":"Hays","year":"2014","journal-title":"Evidence-Based Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0053|cit53","unstructured":"Pharmacogenetics, emotional reactivity and smoking ClinicalTrials.gov\/ct2\/NCT00507728"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/add.14250","article-title":"An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use","volume":"113","author":"Cinciripini","year":"2018","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0055|cit55","unstructured":"Combining varenicline and bupropion for smoking cessation ClinicalTrials.gov\/ct2\/NCT00943618"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0056|cit56","unstructured":"A non-inferiority trial of cytisine versus varenicline for smoking cessation http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ACTRN12616001654448"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2021.7621","article-title":"Effect of cytisine vs varenicline on smoking cessation: a randomized clinical trial","volume":"326","author":"Courtney","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/add.14541","article-title":"The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial","volume":"114","author":"Thomas","year":"2019","journal-title":"Addiction"},{"issue":"22","key":"10.1002\/14651858.CD006103.pub8-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1001\/jama.2022.8274.","article-title":"Effect of varenicline added to counseling on smoking cessation among African American daily smokers: the Kick It at Swope IV randomized clinical trial","volume":"327","author":"Cox","year":"2022","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0060|cit60","volume-title":"Dissertation Abstracts International: Section B: The Sciences and Engineering","volume":"82","author":"Liebmann","year":"2021"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0061|cit61","unstructured":"Advancing tobacco use treatment for African American smokers ClinicalTrials.gov\/show\/NCT02360631"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jsat.2012.01.004","article-title":"Project Impact: a pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino light smokers","volume":"43","author":"De Dios","year":"2012","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"e019878","DOI":"10.1136\/bmjopen-2017-019878","article-title":"Protocol for the mixed-methods process and context evaluation of the TB & Tobacco randomised controlled trial in Bangladesh and Pakistan: a hybrid effectiveness-implementation study","volume":"8","author":"Boeckmann","year":"2018","journal-title":"BMJ Open"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/add.14242","article-title":"The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients-protocol for a double-blind, placebo-controlled randomized trial","volume":"113","author":"Dogar","year":"2018","journal-title":"Addiction"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"e1408","DOI":"10.1016\/S2214-109X(20)30312-0","article-title":"Cytisine for smoking cessation in patients with tuberculosis: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"8","author":"Dogar","year":"2020","journal-title":"Lancet Global Health"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0066|cit66","unstructured":"Tuberculosis (TB) and tobacco www.isrctn.com\/ISRCTN43811467"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0067|cit67","first-page":"74","article-title":"Effect of quitting smoking on health outcomes during treatment for tuberculosis: secondary analysis of the TB & Tobacco Trial","volume":"7","author":"Siddiqi","year":"2021","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0068|cit68","first-page":"8","article-title":"Reports of suicidal ideation and behavior in the EAGLES trial","volume":"SYM5D","author":"Anthenelli","year":"2016","journal-title":"Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March"},{"issue":"10037","key":"10.1002\/14651858.CD006103.pub8-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s11606-019-04858-2","article-title":"Predictors of neuropsychiatric adverse events with smoking cessation medications in the randomized controlled EAGLES trial","volume":"34","author":"Anthenelli","year":"2019","journal-title":"Journal of General Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/da.22982","article-title":"Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial","volume":"37","author":"Ayers","year":"2020","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CEOR.S153897","article-title":"A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial","volume":"10","author":"Baker","year":"2018","journal-title":"ClinicoEconomics and outcomes research"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/add.15440","article-title":"Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors","volume":"116","author":"Beard","year":"2021","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0074|cit74","unstructured":"Benowitz N Evins AE West R St Aubin L McRae T Lawrence D EAGLES trial: study design and neuropsychiatric safety results Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 7"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jamainternmed.2018.0397","article-title":"Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial","volume":"178","author":"Benowitz","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1093\/ntr\/ntab056","article-title":"Psychiatric co-morbidity and multi-morbidity in the EAGLES trial: descriptive correlates and associations with neuropsychiatric adverse events, treatment adherence, and smoking cessation","volume":"23","author":"Correa","year":"2021","journal-title":"Nicotine & Tobacco Research"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub8-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.mayocp.2020.10.046","article-title":"Frequently reported adverse events with smoking cessation medications: post hoc analysis of a randomized trial","volume":"96","author":"Ebbert","year":"2021","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/JCP.0000000000001015","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES trial","volume":"39","author":"Evins","year":"2019","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1176\/appi.ps.202000032","article-title":"Efficacy and safety of pharmacotherapeutic smoking cessation aids in schizophrenia spectrum disorders: subgroup analysis of EAGLES","volume":"72","author":"Evins","year":"2021","journal-title":"Psychiatric Services (Washington, D.C.)"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jad.2019.06.008","article-title":"Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: subgroup analysis of a randomized clinical trial","volume":"256","author":"Heffner","year":"2019","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0081|cit81","unstructured":"A phase 4, randomized, double blind, active and placebo controlled multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks varenicline tartrate 1mg BID and bupropion hydrochloride 150 mg BID for smoking cessation in subjects with and without a history of psychiatric disorders [EAGLES] clinicaltrials.gov\/ct2\/show\/NCT01456936"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"e2032053","DOI":"10.1001\/jamanetworkopen.2020.32053","article-title":"Assessment of racial differences in pharmacotherapy efficacy for smoking cessation: secondary analysis of the EAGLES randomized clinical trial","volume":"4","author":"Nollen","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0083|cit83","first-page":"7","article-title":"Evaluating adverse events in a global smoking cessation study (EAGLES): a randomized controlled trial comparing the safety and efficacy of the first-line smoking cessation aids in smokers with and without psychiatric disorders","volume":"SYM5","author":"Prochaska","year":"2016","journal-title":"Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0084|cit84","first-page":"7","article-title":"Neuropsychiatric risk concerns in the context of smoking, quitting, and cessation pharmacotherapy use","volume":"SYM5A","author":"Prochaska","year":"2016","journal-title":"Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0085|cit85","first-page":"8","article-title":"Relative efficacy of varenicline, bupropion SR, and nicotine transdermal patch in aiding smoking cessation in the EAGLES trial","volume":"SYM5C","author":"West","year":"2016","journal-title":"Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/add.14208","article-title":"Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES","volume":"113","author":"West","year":"2018","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0087|cit87","first-page":"S260","article-title":"A double-blind, active-and placebo-controlled evaluation of the neuropsychiatric safety and efficacy of varenicline and bupropion for smoking cessation in subjects with (pre-existing) psychiatric disorders: an objective blinded analysis","volume":"40","author":"Wilcox","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0088|cit88","unstructured":"Bastian H Comment on Ebbert 2015 'Reduce to Quit' trial www.ncbi.nlm.nih.gov\/pubmed\/?term=25688780"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub8-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.280","article-title":"Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial","volume":"313","author":"Ebbert","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub8-BIB0090|cit90","first-page":"687","article-title":"Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial","volume":"313","author":"Ebbert","year":"2015","journal-title":"Journal of Vascular Surgery"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0091|cit91","unstructured":"A study to evaluate the efficacy and safety of varenicline compared to placebo for smoking cessation through reduction clinicaltrials.gov\/ct2\/show\/NCT01370356"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.clinthera.2017.03.007","article-title":"Efficacy of varenicline for cigarette reduction before quitting in Japanese smokers: a subpopulation analysis of the reduce to quit trial","volume":"39","author":"Nakamura","year":"2017","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0093|cit93","first-page":"S343","article-title":"Smoking cessation through reduction: does it enhance or diminish successful quitting?","volume":"39","author":"Wilcox","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/ntr\/ntw123","article-title":"Varenicline for smoking cessation in light smokers","volume":"18","author":"Ebbert","year":"2016","journal-title":"Nicotine & Tobacco Research"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/add.13855","article-title":"Effect of 0.5 mg versus 1 mg varenicline for smoking cessation: a randomized controlled trial","volume":"112","author":"Fouz-Roson","year":"2017","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0096|cit96","first-page":"PA4478","article-title":"Influence of psychiatric disorders in patients treated with varenicline","volume":"50","author":"Roson","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0097|cit97","first-page":"PA2987","article-title":"Influence of respiratory and cardiovascular diseases on smoking cessation","volume":"50 Suppl 61","author":"Roson","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0098|cit98","first-page":"PA4480","article-title":"Short-term low-dose vs standard-dose varenicline therapy for smoking cessation: a randomized controlled trial","volume":"50","author":"Roson","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.drugalcdep.2015.06.022","article-title":"Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation","volume":"154","author":"Chen","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0100|cit100","unstructured":"Gonzales D Jorenby DE Brandon T Arteaga C Lee TC Delayed quitting, lapse recovery and long-term outcomes for quitters taking varenicline, bupropion and placebo Society for Research on Nicotine and Tobacco Annual Meeting, Portland OR, Feb 27-March 1st 2008"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0101|cit101","unstructured":"Gonzales D Jorenby DE Brandon TH Arteaga C Lee TC Emergent adverse psychiatric symptoms by therapy during 12 weeks of treatment with varenicline, bupropion SR, or placebo for smoking cessation Society for Research on Nicotine and Tobacco Europe: Rome, September 23-26 2008"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/j.1360-0443.2010.03058.x","article-title":"Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo","volume":"105","author":"Gonzales","year":"2010","journal-title":"Addiction"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline, an \u03b14\u00df2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation","volume":"296","author":"Gonzales","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ntr\/ntq047","article-title":"Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence","volume":"12","author":"Hays","year":"2010","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drugalcdep.2009.12.022","article-title":"Predictors of post-treatment relapse to smoking in successful quitters: pooled data from two phase III varenicline trials","volume":"109","author":"Heffner","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JOM.0b013e3180459ff2","article-title":"An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation","volume":"49","author":"Jackson","year":"2007","journal-title":"Journal of Occupational and Environmental Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"664","DOI":"10.5993\/AJHB.32.6.10","article-title":"Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis","volume":"32","author":"Nides","year":"2008","journal-title":"American Journal of Health Behavior"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11920-007-0044-4","article-title":"A new medication for the worst addiction","volume":"9","author":"O'Brien","year":"2007","journal-title":"Current Psychiatry Reports"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/clpt.2009.282","article-title":"Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation","volume":"87","author":"Ravva","year":"2010","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0110|cit110","first-page":"167","article-title":"Practical implementation of varenicline as an aid to smoking cessation in clinical practice","volume":"58","author":"Tonstad","year":"2009","journal-title":"Pneumologia"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0111|cit111","doi-asserted-by":"crossref","unstructured":"West R Baker CL Cappelleri JC Bushmakin AG Effect of varenicline and bupropion on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt UK National Smoking Cessation Conference Proceedings, London, June 2007 2007","DOI":"10.1007\/s00213-007-1041-3"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/11589230-000000000-00000","article-title":"A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data","volume":"29","author":"Xenakis","year":"2011","journal-title":"PharmacoEconomics"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/clpt.2014.124","article-title":"Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial","volume":"96","author":"Gonzales","year":"2014","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0114|cit114","unstructured":"A multi-national study to assess how effective and safe the smoking cessation medicine varenicline is in smokers who have already tried varenicline in the past as a prescription medicine from their usual healthcare provider clinicaltrials.gov\/ct2\/show\/NCT01244061"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub8-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1001\/jamapediatrics.2019.3553","article-title":"Efficacy and safety of varenicline for adolescent smoking cessation: a randomized clinical trial","volume":"173","author":"Gray","year":"2019","journal-title":"JAMA Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/ntr\/ntz170","article-title":"Cannabis and alcohol co-use in a smoking cessation pharmacotherapy trial for adolescents and emerging adults","volume":"22","author":"McClure","year":"2019","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0117|cit117","unstructured":"A randomized controlled trial of varenicline for adolescent smoking cessation ClinicalTrials.gov\/show\/NCT01509547"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"268","DOI":"10.5588\/ijtld.11.0183","article-title":"Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran","volume":"16","author":"Heydari","year":"2012","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0119|cit119","unstructured":"Evaluation of the effect of champ-ix in smoking cessation in smokers in Tehran www.irct.ir\/trial\/1473"},{"issue":"2C","key":"10.1002\/14651858.CD006103.pub8-BIB0120|cit120","first-page":"667","article-title":"Study on effect of 5A intervention method combined with varenicline for smoking cessation of COPD patients in stable stage","volume":"29","author":"Hong","year":"2015","journal-title":"Chinese Nursing Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2017.11.017","article-title":"Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: a randomized controlled trial","volume":"184","author":"Hurt","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0122|cit122","unstructured":"Varenicline treatment for active alcoholic smokers clinicaltrials.gov\/ct2\/show\/NCT01347112"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0123|cit123","first-page":"553","article-title":"Varenicline vs. nicotine replacement therapy: a prospective study of changes in arterial stiffness, endothelial glycocalyx and oxidative stress in smokers during 1 year follow-up","volume":"Suppl 1 Europea","author":"Ikonomidis","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2017.05.012","article-title":"Effects of varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program","volume":"262","author":"Ikonomidis","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0125|cit125","first-page":"242","article-title":"Smoking cessation rates with varenicline and electronic cigarettes in relapsed smokers with a history of acute coronary syndrome","volume":"Suppl 1: Europe","author":"Ioakeimidis","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0126|cit126","first-page":"S52","article-title":"Randomised controlled trial comparing varenicline plus counselling and brief counselling alone on smoking cessation in patients prone to lung cancer using carbon monoxide moniter","volume":"2 Suppl 1: 2017","author":"Johns","year":"2017","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"iii6","DOI":"10.1093\/annonc\/mdx087.004","article-title":"The efficacy of combination therapy with varenicline and bupropion for smoking cessation","volume":"Suppl 2: 7th Eu","author":"Johns","year":"2017","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an \u03b14\u00df2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0129|cit129","first-page":"348","article-title":"A second varenicline trial","volume":"9","author":"O'Brien","year":"2007","journal-title":"Current Psychiatry Reports"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"e220951","DOI":"10.1001\/jamanetworkopen.2022.0951","article-title":"Effect of combination treatment with varenicline and nicotine patch on smoking cessation among smokers who drink heavily: a randomized clinical trial","volume":"5","author":"King","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0131|cit131","unstructured":"Varenicline augmentation of patch outcomes in heavy drinkers' smoking cessation clinicaltrials.gov\/show\/NCT02859142"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15412555.2019.1703928","article-title":"Effect of early initiation of varenicline on smoking cessation in COPD patients admitted for exacerbation: the save randomized clinical trial","volume":"17","author":"Le Mao","year":"2020","journal-title":"COPD"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0133|cit133","unstructured":"Efficacy of varenicline associated with intensive counselling versus placebo of varenicline associated with intensive counselling on smoking cessation at the acute phase of an exacerbation of chronic obstructive pulmonary disease (COPD). A multicenter randomized double-blind trial ClinicalTrials.gov\/show\/NCT01694732"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0134|cit134","first-page":"32","article-title":"Effect of varenicline on smoking cessation in COPD patients recovering from exacerbation: a randomized trial","volume":"32 Suppl 1","author":"Tromeur","year":"2018","journal-title":"Fundamental & Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1017\/jsc.2016.11","article-title":"Sleep disturbance during smoking cessation: withdrawal or side effect of treatment?","volume":"12","author":"Ashare","year":"2017","journal-title":"Journal of Smoking Cessation"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub8-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1037\/adb0000619","article-title":"Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV","volume":"35","author":"Ashare","year":"2021","journal-title":"Psychology of Addictive Behaviors"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/1055-9965.EPI-14-0427","article-title":"Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers","volume":"23","author":"Chenoweth","year":"2014","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/ntr\/ntv125","article-title":"The nicotine metabolite ratio is associated with early smoking abstinence even after controlling for factors that influence the nicotine metabolite ratio","volume":"18","author":"Chenoweth","year":"2016","journal-title":"Nicotine & Tobacco Research"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S2213-2600(14)70294-2","article-title":"Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial","volume":"3","author":"Lerman","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0140|cit140","unstructured":"Pharmacogenetics of nicotine addiction treatment clinicaltrials.gov\/ct2\/show\/NCT01314001"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drugalcdep.2018.04.035","article-title":"Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: impact on pharmacogenetic trial outcomes","volume":"190","author":"Peng","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/add.14810","article-title":"Impact of early nausea on varenicline adherence and smoking cessation","volume":"115","author":"Peng","year":"2020","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0143|cit143","article-title":"Measures of adherence to varenicline: impact on smoking cessation outcomes","volume":"82","author":"Peng","year":"2021","journal-title":"Dissertation Abstracts International"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1037\/adb0000434","article-title":"Evaluating the temporal relationships between withdrawal symptoms and smoking relapse","volume":"33","author":"Robinson","year":"2019","journal-title":"Psychology of Addictive Behaviors"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"e0128109","DOI":"10.1371\/journal.pone.0128109","article-title":"Lack of associations of CHRNA5-A3-B4 genetic variants with smoking cessation treatment outcomes in Caucasian smokers despite associations with baseline smoking","volume":"10","author":"Tyndale","year":"2015","journal-title":"Plos One"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drugalcdep.2017.06.020","article-title":"ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation","volume":"179","author":"Bidwell","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0147|cit147","first-page":"S278","article-title":"ADHD symptoms moderate the efficacy of verenacline in a randomized controlled trial","volume":"41","author":"Cinnamon Bidwell","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"23-24","key":"10.1002\/14651858.CD006103.pub8-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s00213-017-4721-7","article-title":"Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo","volume":"234","author":"Littlewood","year":"2017","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/S2352-3018(18)30002-X","article-title":"Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial","volume":"5","author":"Mercie","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0150|cit150","first-page":"56","article-title":"Varenicline vs placebo for smoking cessation: ANRS 144 Inter-ACTIV randomized trial","volume":"23","author":"Mercie","year":"2015","journal-title":"Topics in Antiviral Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0151|cit151","unstructured":"Efficacy and safety of varenicline amongst HIV-infected patients (Inter-ACTIV) ClinicalTrials.gov\/show\/NCT00918307"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/ntr\/ntu267","article-title":"Barriers to telephone quitline use among methadone-maintained smokers","volume":"17","author":"Griffin","year":"2015","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0153|cit153","unstructured":"Smoking cessation treatment for methadone maintenance patients clinicaltrials.gov\/ct2\/show\/NCT01027754"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/add.12631","article-title":"Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial","volume":"109","author":"Nahvi","year":"2014","journal-title":"Addiction"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1185\/03007995.2010.505130","article-title":"Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries","volume":"26","author":"Fagerstr\u00f6m","year":"2010","journal-title":"Current Medical Research & Opinion"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00019053-200927030-00007","article-title":"Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan","volume":"27","author":"Igarashi","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.clinthera.2007.06.012","article-title":"Efficacy and tolerability of nicotinic varenicline, an alpha4beta2 acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers","volume":"29","author":"Nakamura","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.clinthera.2014.03.013","article-title":"Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers","volume":"36","author":"Nakamura","year":"2014","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0159|cit159","unstructured":"Maintaining nonsmoking ClinicalTrials.gov\/show\/NCT01162239"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub8-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1185\/03007990802177523","article-title":"The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial","volume":"24","author":"Niaura","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"664","DOI":"10.5993\/AJHB.32.6.10","article-title":"Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis","volume":"32","author":"Nides","year":"2008","journal-title":"American Journal of Health Behavior"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.166.15.1561","article-title":"Smoking cessation with varenicline, a selective \u03b14\u03b22 nicotinic receptor partial agonist","volume":"166","author":"Nides","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0163|cit163","unstructured":"Oncken C Watsky E Reeves K Anziano R Varenicline is efficacious and well tolerated in promoting smoking cessation: results from a 7-week, randomized, placebo- and bupropion-controlled trial [POS1-047] Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic 2005"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/acer.13994","article-title":"Longitudinal findings from a randomized clinical trial of varenicline for alcohol use disorder with comorbid cigarette smoking","volume":"43","author":"Bold","year":"2019","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0165|cit165","unstructured":"1\/2-multi-site study: varenicline treatment of alcohol dependent smokers ClinicalTrials.gov\/show\/NCT01553136"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jamapsychiatry.2017.3544","article-title":"Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial","volume":"75","author":"O'Malley","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"15","key":"10.1002\/14651858.CD006103.pub8-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/archinte.166.15.1571","article-title":"Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation","volume":"166","author":"Oncken","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0168|cit168","unstructured":"Oncken C Watsky E Reeves K Anziano R Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: results from a phase 2 study [POS1-046] Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic 2005"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jtho.2022.07.007.","article-title":"Cytisine therapy improved smoking cessation in the randomized SMILE lung cancer screening trial","volume":"17","author":"Pastorino","year":"2022","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0170|cit170","unstructured":"Individual tobacco cessation research based on nicotine metabolite ratio in smoking patients with chronic obstructive pulmonary disease: a randomized controlled trial https:\/\/trialsearch.who.int\/Trial2.aspx? TrialID=ChiCTR1900021400"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2147\/COPD.S301579","article-title":"Adherence and efficacy of smoking cessation treatment among patients with COPD in China","volume":"16","author":"Qin","year":"2021","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jsat.2013.08.015","article-title":"Association of deferring a quit attempt with smoking cessation success: a secondary analysis","volume":"46","author":"Hughes","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub8-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.addbeh.2011.08.001","article-title":"Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: a cross-study analysis","volume":"36","author":"Hughes","year":"2011","journal-title":"Addictive Behaviors"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ntr\/ntr220","article-title":"A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates","volume":"14","author":"Rennard","year":"2012","journal-title":"Nicotine & Tobacco Research"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/CIRCULATIONAHA.109.915546","article-title":"Varenicline for smoking cessation in patients with coronary heart disease [editorial]","volume":"121","author":"Ockene","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0176|cit176","first-page":"2","article-title":"A randomized trial of varenicline for smoking cessation in patients with cardiovascular disease: analysis of efficacy by baseline characteristics","volume":"Conference","author":"Rigotti","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/CIRCULATIONAHA.109.869008","article-title":"Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease","volume":"121","author":"Rigotti","year":"2010","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1161\/CIRCULATIONAHA.110.960856","article-title":"Response to letter regarding article, efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial","volume":"122","author":"Rigotti","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jsat.2019.06.005","article-title":"Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement","volume":"104","author":"Martin","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0180|cit180","unstructured":"Varenicline and motivational advice for smokers with substance use disorders ClinicalTrials.gov\/ct2\/show\/NCT00756275"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.drugalcdep.2015.07.515","article-title":"Varenicline versus nicotine patch plus brief advice for sober smokers in substance treatment","volume":"156","author":"Rohsenow","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0182|cit182","unstructured":"Rohsenow DJ Tidey JW Martin RA Colby SM Monti PM Varenicline helps smokers with SUD stop smoking without harming recovery (POS5-63) Society for Research on Nicotine and Tobacco 21st Annual Meeting February 25-28 Philadelphia 2015"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/add.13861","article-title":"Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms","volume":"112","author":"Rohsenow","year":"2017","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0184|cit184","unstructured":"Evaluation of a tailored smoking cessation treatment algorithm based on initial treatment response and genotype (ConNIC3) clinicaltrials.gov\/ct2\/show\/NCT00894166"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1176\/appi.ajp.2013.12070919","article-title":"Adapting smoking cessation treatment according to initial response to precessation nicotine patch","volume":"170","author":"Rose","year":"2013","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/mp.2012.155","article-title":"Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances","volume":"19","author":"Uhl","year":"2014","journal-title":"Molecular Psychiatry"},{"issue":"44","key":"10.1002\/14651858.CD006103.pub8-BIB0187|cit187","first-page":"2092","article-title":"Results of smoking cessation treatment with cytisin (Tabex\u00ae)","volume":"23","author":"Benndorf","year":"1968","journal-title":"Das Deutsche Gesundheitwesen"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0188|cit188","first-page":"774","article-title":"Smoking cessation treatment with cytisin (Tabex\u00ae): half-yearly outcomes for former smokers abstinent at four weeks from beginning of treatment","volume":"24","author":"Benndorf","year":"1970","journal-title":"Das Deutsche Gesundheitwesen"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0189|cit189","first-page":"1135","article-title":"Further reports on a double blind trial of the Bulgarian cytisine compound Tabex\u00ae on 1214 smokers wishing to quit and practical experience in conducting clinics for such smokers","volume":"24","author":"Benndorf","year":"1969","journal-title":"Das Deutsche Gesundheitswesen"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0190|cit190","first-page":"463","article-title":"Cytisine (Tabex\u00ae) as a treatment for smoking cessation","volume":"26","author":"Scharfenberg","year":"1971","journal-title":"Das Deutsche Gesundheitwesen"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/pon.4483","article-title":"Cancer-related disease factors and smoking cessation treatment: analysis of an ongoing clinical trial","volume":"27","author":"Carroll","year":"2018","journal-title":"Psycho-oncology"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/ntr\/nty133","article-title":"Predictors of varenicline adherence among cancer patients treated for tobacco dependence and its association with smoking cessation","volume":"21","author":"Crawford","year":"2019","journal-title":"Nicotine & Tobacco Research"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1188\/21.ONF.112-120","article-title":"Change in health-related quality of life among individuals with cancer undergoing smoking cessation treatment involving varenicline","volume":"48","author":"May","year":"2021","journal-title":"Oncology Nursing Forum"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0194|cit194","unstructured":"Extended duration varenicline for smoking among cancer patients: a clinical trial ClinicalTrials.gov\/show\/NCT01756885"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/pon.4978","article-title":"A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: efficacy, safety, and adherence","volume":"28","author":"Schnoll","year":"2019","journal-title":"Psycho-oncology"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/ntr\/ntu099","article-title":"Early quit days among methadone-maintained smokers in a smoking cessation trial","volume":"16","author":"De Dios","year":"2014","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0197|cit197","unstructured":"Varenicline versus nicotine replacement for methadone-maintained smokers https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00790569"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.drugalcdep.2013.07.005","article-title":"Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial","volume":"133","author":"Stein","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub8-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.addbeh.2011.07.002","article-title":"Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline","volume":"36","author":"Steinberg","year":"2011","journal-title":"Addictive Behaviors"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0200|cit200","unstructured":"Varenicline-aided cigarette reduction in smokers not ready to quit ClinicalTrials.gov\/show\/NCT01308736"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addbeh.2018.03.026","article-title":"Varenicline for smoking reduction in smokers not yet ready to quit: a double-blind, proof-of-concept randomized clinical trial","volume":"84","author":"Steinberg","year":"2018","journal-title":"Addictive Behaviors"},{"issue":"16","key":"10.1002\/14651858.CD006103.pub8-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1517\/14656566.2011.605786","article-title":"Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease","volume":"12","author":"Antoniu","year":"2011","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1378\/chest.10-2919","article-title":"What justifies a placebo-controlled trial of varenicline for smoking cessation in patients with COPD? [comment]","volume":"139","author":"Kotz","year":"2011","journal-title":"Chest"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1378\/chest.10-0865","article-title":"Effects of varenicline on smoking cessation in mild-to-moderate COPD: a randomized controlled trial","volume":"139","author":"Tashkin","year":"2011","journal-title":"Chest"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.rmed.2011.04.016","article-title":"Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients","volume":"105","author":"Tashkin","year":"2011","journal-title":"Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ntr\/ntq191","article-title":"Dianicline, a novel \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial","volume":"13","author":"Tonstad","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1185\/03007995.2010.505130","article-title":"Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries","volume":"26","author":"Fagerstr\u00f6m","year":"2010","journal-title":"Current Medical Research & Opinion"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.clinthera.2007.06.011","article-title":"A randomized, placebo-controlled trial of varenicline, a selective \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers","volume":"29","author":"Billing","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1253\/circj.CJ-10-0165","article-title":"Smoking is a disease and smokers are patients","volume":"74","author":"Fujiwara","year":"2010","journal-title":"Circulation Journal"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1253\/circj.CJ-09-0803","article-title":"A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers","volume":"74","author":"Tsukahara","year":"2010","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0211|cit211","unstructured":"Smoking cessation in young adults in Northern Finland ClinicalTrials.gov\/show\/NCT01531049"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcpt.12548","article-title":"Varenicline and nicotine patch therapies in young adults motivated to quit smoking: a randomized, placebo-controlled, prospective study","volume":"119","author":"Tuisku","year":"2016","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881118773532","article-title":"Nicotine metabolite ratio and smoking outcomes using nicotine replacement therapy and varenicline among smokers with and without psychiatric illness","volume":"32","author":"Clyde","year":"2018","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1037\/adb0000250","article-title":"Factor structure of the Smoking Cessation Self-Efficacy Questionnaire among smokers with and without a psychiatric diagnosis","volume":"31","author":"Clyde","year":"2017","journal-title":"Psychology of Addictive Behaviors"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0215|cit215","unstructured":"Reducing cardiovascular disease by combining smoking cessation pharmacotherapy and behavioural counselling clinicaltrials.gov\/ct2\/show\/NCT01623505"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cct.2014.05.011","article-title":"Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial","volume":"38","author":"Tulloch","year":"2014","journal-title":"Contemporary Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.amepre.2015.11.006","article-title":"The quit experience and concerns of smokers with psychiatric illness","volume":"50","author":"Tulloch","year":"2016","journal-title":"American Journal of Preventive Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12916-016-0626-2","article-title":"Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial","volume":"14","author":"Tulloch","year":"2016","journal-title":"BMC Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0219|cit219","first-page":"E21","article-title":"Do women and men differ in baseline smoking characteristics and quit rates following treatment with smoking cessation medications? A secondary analysis of the flex study","volume":"38","author":"Zhang","year":"2018","journal-title":"Journal of Cardiopulmonary Rehabilitation and Prevention. Conference: 2018 Fall Conference of the Canadian Association of Cardiovascular Prevention and Rehabilitation, CACPR 2018. Canada"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1375\/jsc.3.1.57","article-title":"A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers","volume":"3","author":"Vinnikov","year":"2008","journal-title":"Journal of Smoking Cessation"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1186\/1471-2458-11-880","article-title":"Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking","volume":"11","author":"Walker","year":"2011","journal-title":"BMC Public Health"},{"issue":"25","key":"10.1002\/14651858.CD006103.pub8-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1056\/NEJMoa1407764","article-title":"Cytisine versus nicotine for smoking cessation","volume":"371","author":"Walker","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0223|cit223","unstructured":"Cytisine versus varenicline for smoking cessation clinicaltrials.gov\/show\/NCT02957786"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/add.14449","article-title":"Cytisine versus varenicline for smoking cessation for Maori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non-inferiority trial","volume":"114","author":"Walker","year":"2019","journal-title":"Addiction"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1111\/add.15489","article-title":"Cytisine versus varenicline for smoking cessation in New Zealand indigenous Maori: a randomized controlled trial","volume":"116","author":"Walker","year":"2021","journal-title":"Addiction"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1185\/03007995.2010.505130","article-title":"Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries","volume":"26","author":"Fagerstr\u00f6m","year":"2010","journal-title":"Current Medical Research & Opinion"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1440-1843.2008.01476.x","article-title":"Varenicline for smoking cessation: a placebo-controlled, randomized study","volume":"14","author":"Wang","year":"2009","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1102035","article-title":"Placebo-controlled trial of cytisine for smoking cessation","volume":"365","author":"West","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"JC1","DOI":"10.7326\/0003-4819-156-2-201201170-02006","article-title":"Cytisine increased smoking cessation in adults","volume":"156","author":"West","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/cea.12243","article-title":"The effect of smoking cessation on airway inflammation in young asthma patients","volume":"44","author":"Westergaard","year":"2013","journal-title":"Clinical & Experimental Allergy"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0231|cit231","first-page":"A1091","article-title":"The effect of varenicline on smoking cessation in a group of young asthma patients","volume":"189","author":"Westergaard","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0232|cit232","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.rmed.2015.07.017","article-title":"The effect of varenicline on smoking cessation in a group of young asthma patients","volume":"109","author":"Westergaard","year":"2015","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0233|cit233","unstructured":"Reeves K Watsky E Williams K Azoulay S Billing B Gong J The safety of varenicline taken for 52 weeks for smoking cessation [RPOS3-54] Society for Research on Nicotine and Tobacco 12th Annual Conference Orlando Fla, USA 2006"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1185\/030079908X261140","article-title":"Comment and reply: a double-blind study evaluating the long-term safety of varenicline for smoking cessation","volume":"24","author":"Spangler","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1185\/030079907X182185","article-title":"A double-blind study evaluating the long-term safety of varenicline for smoking cessation","volume":"23","author":"Williams","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0236|cit236","unstructured":"Smoking cessation study for patients with schizophrenia or schizoaffective disorder clinicaltrials.gov\/ct2\/show\/NCT00644969"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.11m07522","article-title":"A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder","volume":"73","author":"Williams","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"e004785","DOI":"10.1161\/JAHA.116.004785","article-title":"Smokers and postcessation weight gain after acute coronary syndrome","volume":"6","author":"Dehghani","year":"2017","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.115.019634","article-title":"Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome","volume":"133","author":"Eisenberg","year":"2016","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0240|cit240","unstructured":"Evaluation of varenicline (Champix) in smoking cessation for patients post-acute coronary syndrome (EVITA) trial (EVITA) clinicaltrials.gov\/ct2\/show\/NCT00794573"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2015.07.010","article-title":"A randomized controlled trial of the efficacy and safety of varenicline for smoking cessation after acute coronary syndrome: design and methods of the Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome trial","volume":"170","author":"Windle","year":"2015","journal-title":"American Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub8-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"E347","DOI":"10.1503\/cmaj.170377","article-title":"Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital","volume":"190","author":"Windle","year":"2018","journal-title":"CMAJ : Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.cjca.2016.07.159","article-title":"Sustained smoking abstinence 12 months after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in hospitalized patients","volume":"10 Suppl 1","author":"Windle","year":"2016","journal-title":"Canadian Journal of Cardiology. Conference: 69th Annual Meeting of the Canadian Cardiovascular Society. Canada."},{"key":"10.1002\/14651858.CD006103.pub8-BIB0244|cit244","unstructured":"Smoking cessation program in the pre-admission clinic clinicaltrials.gov\/ct2\/show\/NCT00937508"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/ALN.0b013e3182698b42","article-title":"A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial","volume":"117","author":"Wong","year":"2012","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0246|cit246","first-page":"385","article-title":"Assessment of efficacy of medication combined with WeChat platform for quitting smoking in patients with chronic obstructive pulmonary disease","volume":"36","author":"Yang","year":"2016","journal-title":"Journal of Shanghai Jiaotong University (Medical Science)"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0247|cit247","unstructured":"Varenicline in residential treatment (ViRT) clinicaltrials.gov\/ct2\/show\/NCT01286584"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/JCP.0000000000001172","article-title":"Safety and efficacy of varenicline for smoking cessation in alcohol-dependent smokers in concurrent treatment for alcohol use disorder: a pilot, randomized placebo-controlled trial","volume":"40","author":"Zawertailo","year":"2020","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0249|cit249","unstructured":"The MATCH (Medication Aids for Tobacco Cessation and Health) study clinicaltrials.gov\/show\/NCT02146911"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"e10826","DOI":"10.2196\/10826","article-title":"Varenicline and bupropion for long-term smoking cessation (the MATCH Study): protocol for a real-world, pragmatic, randomized controlled trial","volume":"7","author":"Zawertailo","year":"2018","journal-title":"JMIR Research Protocols"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"109312","DOI":"10.1016\/j.drugalcdep.2022.109312","article-title":"Evaluating the effectiveness of bupropion and varenicline for smoking cessation using an internet-based delivery system: a pragmatic randomized controlled trial (MATCH study)","volume":"232","author":"Zhang","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5455\/bcp.20130313045037","article-title":"Comparison of the effectiveness of varenicline, extended-release bupropion and nicotine replacement therapy on the success and the maintenance of a smoking cessation program","volume":"23","author":"Zincir","year":"2013","journal-title":"Bulletin of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-011-2327-z","article-title":"Varenicline effects on craving, cue reactivity, and smoking reward","volume":"218","author":"Brandon","year":"2011","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s12889-018-5351-7","article-title":"The effectiveness and safety of combining varenicline with nicotine e-cigarettes for smoking cessation in people with mental illnesses and addictions: study protocol for a randomised-controlled trial","volume":"18","author":"Bullen","year":"2018","journal-title":"BMC Public Health"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1177\/0091270006291837","article-title":"Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers","volume":"46","author":"Burstein","year":"2006","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0256|cit256","unstructured":"Chantix prescribing information www.chantix.com\/content\/Prescribing_Information.jsp"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0257|cit257","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1089\/apc.2011.0199","article-title":"Safety and tolerability of varenicline tartrate (Champix\u00ae\/Chantix\u00ae) for smoking cessation in HIV-infected subjects: a pilot open-label study","volume":"26","author":"Cui","year":"2012","journal-title":"AIDS Patient Care and STDs"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0258|cit258","first-page":"356","article-title":"Use of the patient health questionnaire-2 to predict suicidal ideations in patients taking varenicline","volume":"21","author":"Cowan","year":"2012","journal-title":"American Journal on Addictions \/ American Academy of Psychiatrists in Alcoholism and Addictions"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7205\/MILMED-D-12-00272","article-title":"Internet versus in-person counseling for patients taking varenicline for smoking cessation","volume":"178","author":"Dezee","year":"2013","journal-title":"Military Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0260|cit260","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00213-011-2373-6","article-title":"Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity","volume":"219","author":"Dutra","year":"2012","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ntr\/ntn031","article-title":"Varenicline and bupropion sustained-release combination therapy for smoking cessation","volume":"11","author":"Ebbert","year":"2009","journal-title":"Nicotine & Tobacco Research"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/ntr\/ntp042","article-title":"Combination treatment with varenicline and nicotine replacement therapy","volume":"11","author":"Ebbert","year":"2009","journal-title":"Nicotine & Tobacco Research"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/ntr\/ntr078","article-title":"A pilot study to assess smokeless tobacco use reduction with varenicline","volume":"13","author":"Ebbert","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jama.2013.283185","article-title":"Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial","volume":"311","author":"Ebbert","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0265|cit265","unstructured":"Varenicline and bupropion for smoking cessation (CHANBAN) clinicaltrials.gov\/ct2\/show\/NCT00935818"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/15504263.2017.1319585","article-title":"Improved depressive symptoms in adults with schizophrenia during a smoking cessation attempt with varenicline and behavioral therapy","volume":"13","author":"Cather","year":"2017","journal-title":"Journal of Dual Diagnosis"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.2013.285113","article-title":"Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial","volume":"311","author":"Evins","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0268|cit268","first-page":"S63","article-title":"Extended duration pharmacotherapy with varenicline prevents relapse to smoking in adult smokers with schizophrenia","volume":"38","author":"Evins","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0269|cit269","unstructured":"A study of varenicline for prevention of relapse to smoking in patients with schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00621777"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/15504263.2012.663675","article-title":"Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week open-label trial","volume":"8","author":"Pachas","year":"2012","journal-title":"Journal of Dual Diagnosis"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.4088\/JCP.15m10074","article-title":"Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial","volume":"77","author":"Thorndike","year":"2016","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"AP008","DOI":"10.1161\/circ.131.suppl_1.p008","article-title":"Weight gain and cardiovascular risk reduction associated with tobacco abstinence in smokers with serious mental illness","volume":"131","author":"Thorndike","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clinthera.2009.01.003","article-title":"Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"31","author":"Faessel","year":"2009","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0274|cit274","doi-asserted-by":"publisher","first-page":"c6549","DOI":"10.1136\/bmjc6549","article-title":"Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial","volume":"341","author":"Fagerstr\u00f6m","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0275|cit275","first-page":"139A","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"38 Suppl s1","author":"Falk","year":"2014","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"7","author":"Litten","year":"2013","journal-title":"Journal of Addiction Medicine"},{"issue":"1-3","key":"10.1002\/14651858.CD006103.pub8-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.schres.2013.02.015","article-title":"Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study","volume":"146","author":"Fatemi","year":"2013","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0278|cit278","unstructured":"Varenicline and smoking cessation in schizophrenia (VSCS) clinicaltrials.gov\/ct2\/show\/NCT01111149"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2011.10.011","article-title":"A pilot test of a combined tobacco dependence treatment and lung cancer screening program","volume":"76","author":"Ferketich","year":"2012","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ntr\/nts121","article-title":"Safety of varenicline among smokers enrolled in the lung HIV study","volume":"15","author":"Ferketich","year":"2013","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0281|cit281","first-page":"80A","article-title":"Moderators of the varenicline treatment effect in a double-blind, placebo controlled trial for alcohol dependence","volume":"39","author":"Fertig","year":"2015","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/JCP.0b013e31829cc3cd","article-title":"A feasibility study of varenicline for smoking cessation in bipolar patients with subsyndromal depression","volume":"33","author":"Frye","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00213-010-2160-9","article-title":"A preliminary investigation of varenicline for heavy drinking smokers","volume":"215","author":"Fucito","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.biopsych.2010.12.005","article-title":"A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo","volume":"69","author":"Garza","year":"2011","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0285|cit285","first-page":"8","article-title":"Smoking cessation through the use of cytisine and other therapy","volume":"1","author":"Granatowicz","year":"1976","journal-title":"World Smoking Health"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ntr\/ntr130","article-title":"Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial","volume":"14","author":"Gray","year":"2012","journal-title":"Nicotine & Tobacco Research"},{"issue":"19","key":"10.1002\/14651858.CD006103.pub8-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1001\/archinternmed.2011.493","article-title":"Is varenicline effectiveness declining in randomized trials?","volume":"171","author":"Dhelaria","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD006103.pub8-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archinternmed.2011.494","article-title":"Is varenicline effectiveness declining in randomized trials? - Reply","volume":"171","author":"Hajek","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/archinternmed.2011.138","article-title":"Use of varenicline for 4 weeks before quitting smoking","volume":"171","author":"Hajek","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archinternmed.2011.137","article-title":"Smoking cessation interventions: a primer for physicians","volume":"171","author":"Simon","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1741-7015-11-140","article-title":"Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial","volume":"11","author":"Hajek","year":"2013","journal-title":"BMC Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0292|cit292","first-page":"143","article-title":"Erratum: increasing varenicline dose in smokers WHO do not respond to the standard dosage: a randomized clinical trial (JAMA internal medicine (2015) 175: 2 (266-271))","volume":"176","author":"Hajek","year":"2016","journal-title":"JAMA Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamainternmed.2014.6916","article-title":"Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial","volume":"175","author":"Hajek","year":"2015","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0294|cit294","first-page":"223A","article-title":"Pharmacogenetics of naltrexone and varenicline in heavy drinking smokers","volume":"38 Suppl s1","author":"Hartwell","year":"2014","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pbb.2015.04.013","article-title":"Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers","volume":"134","author":"Roche","year":"2015","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/clpt.2011.317","article-title":"The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial","volume":"91","author":"Hawk","year":"2012","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0297|cit297","unstructured":"An alternative dosing schedule for varenicline for smoking cessation clinicaltrials.gov\/ct2\/show\/NCT00835900"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub8-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2011.83","article-title":"Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder","volume":"68","author":"Hong","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0299|cit299","unstructured":"Varenicline adjunctive treatment in schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00492349"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/add.12573","article-title":"Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial","volume":"109","author":"Hoogsteder","year":"2014","journal-title":"Addiction"},{"issue":"14","key":"10.1002\/14651858.CD006103.pub8-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s00213-014-3482-9","article-title":"Varenicline versus transdermal nicotine patch: a 3-year follow-up in a smoking cessation clinic in Taiwan","volume":"231","author":"McEwen","year":"2014","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub8-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/ntr\/ntab018","article-title":"Effectiveness of varenicline versus combination nicotine replacement therapy for smoking cessation: one-year outcomes in a smoking cessation clinic in Taiwan","volume":"23","author":"Hsueh","year":"2021","journal-title":"Nicotine & Tobacco Research"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/ntr\/ntr103","article-title":"Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial","volume":"13","author":"Hughes","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0304|cit304","unstructured":"Efficacy of varenicline in ambivalent smokers ClinicalTrials.gov\/ct2\/show\/NCT00595868"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0305|cit305","unstructured":"Cytisine versus nicotine for smoking cessation in hospitalized psychiatric patients http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=IRCT20100127003210N16"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ntr\/ntt115","article-title":"A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India","volume":"16","author":"Jain","year":"2014","journal-title":"Nicotine & Tobacco Research"},{"issue":"21","key":"10.1002\/14651858.CD006103.pub8-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/eurheartj\/ehu051","article-title":"Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial","volume":"35","author":"Jennings","year":"2014","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD006103.pub8-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.mayocp.2013.08.015","article-title":"Increasing the dose of varenicline in patients who do not respond to the standard dose","volume":"88","author":"Jim\u00e9nez-Ruiz","year":"2013","journal-title":"Mayo Clinic Proceedings"},{"issue":"50","key":"10.1002\/14651858.CD006103.pub8-BIB0309|cit309","first-page":"2663","article-title":"Smoking cessation through medication: remarks on G. Scharfenberg, E Winkelvoss and S. Benndorf, Munch Med Wschr. 109 (1967) 1687-1689","volume":"109","author":"Bacvarov","year":"1967","journal-title":"Munchener Medizinische Wochenschrift"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0310|cit310","first-page":"355","article-title":"Observation about the Bulgarian medicine for smoking withdrawal Tabex, produced by Pharmachim-Sofia","volume":"18","author":"Kempe","year":"1967","journal-title":"Savr Med"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0311|cit311","first-page":"26","article-title":"Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: A randomized clinical trial. [German]","volume":"11","author":"Koegelenberg","year":"2014","journal-title":"Zeitschrift fur Gefassmedizin"},{"issue":"24","key":"10.1002\/14651858.CD006103.pub8-BIB0312|cit312","first-page":"2207","article-title":"Therapeutic use of Tabex","volume":"25","author":"Maliszewski","year":"1972","journal-title":"Wiadomoscie Lekarskie"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0313|cit313","first-page":"55","article-title":"Treatment of nicotinism","volume":"1","author":"Marakulin","year":"1984","journal-title":"Voenno-Meditsinskii Zhurnal"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ntr\/nts101","article-title":"Effects of varenicline on abstinence and smoking reward following a programmed lapse","volume":"15","author":"McClure","year":"2013","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0315|cit315","unstructured":"Varenicline for relapse prevention ClinicalTrials.gov\/ct2\/"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.clpt.6100510","article-title":"Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers","volume":"83","author":"McColl","year":"2008","journal-title":"Clinical Therapeutics and Pharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1186\/1471-2458-13-824","article-title":"Extended interactive voice response telephony (IVR) for relapse prevention after smoking cessation using varenicline and IVR: a pilot study","volume":"13","author":"McNaughton","year":"2013","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/JCP.0b013e3182870551","article-title":"Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial","volume":"33","author":"Meszaros","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0319|cit319","first-page":"393","article-title":"Varenicline treatment of alcohol and nicotine dependence in schizophrenia: problems encountered in a pilot trial","volume":"21","author":"Meszaros","year":"2012","journal-title":"American Journal on Addictions \/ American Academy of Psychiatrists in Alcoholism and Addictions"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0320|cit320","unstructured":"Varenicline treatment in alcohol and nicotine dependent patients with schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00727103"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0321|cit321","first-page":"109","article-title":"Pharmacological agents in controlling smoking","volume":"10","author":"Metelitsa","year":"1987","journal-title":"Biulleten Vsesoiuznogo Kardiologicheskogo Nuachnogo Tsentra AMN SSSR"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00213-012-2717-x","article-title":"Varenicline decreases alcohol consumption in heavy-drinking smokers","volume":"223","author":"Mitchell","year":"2012","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/npp.2012.205","article-title":"Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study","volume":"38","author":"Mocking","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0324|cit324","unstructured":"Monova A Monova D Petrov V Peneva E Todorova M Petrova M Final report on double blind, placebo controlled, randomized clinical study for evaluation of efficacy, safety and tolerability of Tabex in patients with chronic nicotinism (tabacism): TAB - SPH - 04014 Sopharma plc unpublished report 2004"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1940-0640-9-9","article-title":"Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics","volume":"9","author":"Nahvi","year":"2014","journal-title":"Addiction Science & Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/add.15240","article-title":"Effect of varenicline directly observed therapy versus varenicline self-administered therapy on varenicline adherence and smoking cessation in methadone-maintained smokers: a randomized controlled trial","volume":"116","author":"Nahvi","year":"2020","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0327|cit327","unstructured":"Efficacy and safety of dianicline treatment as an aid to smoking cessation in cigarette smokers (AMERIDIAN) clinicaltrials.gov\/ct2\/show\/NCT00387946"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0328|cit328","unstructured":"Naltrexone and varenicline: weight gain and tolerability in smokers ClinicalTrials.gov\/show\/NCT00502216"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0329|cit329","unstructured":"Comparison of varenicline and placebo for smoking cessation in schizophrenia ClinicalTrials.gov\/ct2\/show\/NCT00554840"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0330|cit330","unstructured":"Long-term varenicline treatment for smoking cessation clinicaltrials.gov\/ct2\/show\/NCT00828113"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0331|cit331","unstructured":"Study of varenicline for smoking cessation\/reduction in patients with bipolar disorder clinicaltrials.gov\/ct2\/show\/NCT01093937"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0332|cit332","unstructured":"A two-part pilot study of dosing, safety and efficacy of varenicline initiated during an acute smoke-free hospitalization and continued post-hospitalization clinicaltrials.gov\/show\/NCT01413516"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0333|cit333","unstructured":"Treatment of tobacco dependence in breast cancer patients: a randomized trial of varenicline (Chantix) ClinicalTrials.gov\/show\/NCT01532232"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0334|cit334","unstructured":"Study to evaluate cardiac assessments following different treatments of smoking cessation medications in subjects with and without psychiatric disorders [CATS] ClinicalTrials.gov\/show\/NCT01574703"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0335|cit335","unstructured":"Tailored tobacco cessation program for rural veterans with comorbid depression, alcoholism or obesity ClinicalTrials.gov\/show\/NCT01592695"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0336|cit336","unstructured":"Varenicline for light smokers (ChanLight) clinicaltrials.gov\/ct2\/show\/NCT01639560"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0337|cit337","unstructured":"Pilot study of varenicline vs. nicotine patch delivered by a telephone quitline to promote smoking cessation ClinicalTrials.gov\/show\/NCT01771627"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0338|cit338","unstructured":"A combination of scheduled reduced smoking with varenicline to enhance cessation ClinicalTrials.gov\/show\/NCT01772641"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0339|cit339","unstructured":"Combination bupropion\/varenicline for smoking cessation in male smokers ClinicalTrials.gov\/show\/NCT01806779"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0340|cit340","unstructured":"Tailored tobacco intervention ClinicalTrials.gov\/show\/NCT01892813"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0341|cit341","unstructured":"Optimization of smoking cessation strategies in community cancer programs for newly diagnosed lung and head and neck cancer patients Clinicaltrials.gov\/show\/NCT02048917"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0342|cit342","unstructured":"A pilot randomized, placebo-controlled, crossover study of the effect of the nicotine nasal spray and varenicline on cigarette smoking following methadone dosing in methadone-maintained patients ClinicalTrials.gov\/show\/NCT02147132"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0343|cit343","unstructured":"Varenicline and combined nicotine replacement therapy (NRT) for initial smoking cessation and rescue Treatment in smokers: a randomized pilot trial ClinicalTrials.gov\/show\/NCT02271919"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0344|cit344","unstructured":"Adaptive pharmacotherapy for smoking cessation https:\/\/clinicaltrials.gov\/show\/NCT02501265"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0345|cit345","unstructured":"Trial of cytisine in adult smokers clinicaltrials.gov\/ct2\/show\/NCT03709823"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/ntr\/ntab073","article-title":"A multicenter, double-blind, randomized, placebo-controlled phase 2b trial of cytisinicline in adult smokers (the ORCA-1 trial)","volume":"23","author":"Nides","year":"2021","journal-title":"Nicotine & Tobacco Research"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ntr\/ntr333","article-title":"Adherence to varenicline among African American smokers: an exploratory analysis comparing plasma concentration, pill count, and self-report","volume":"14","author":"Buchanan","year":"2012","journal-title":"Nicotine & Tobacco Research"},{"issue":"9","key":"10.1002\/14651858.CD006103.pub8-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/ntr\/ntr063","article-title":"A pilot clinical trial of varenicline for smoking cessation in Black smokers","volume":"13","author":"Nollen","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0349|cit349","first-page":"42","article-title":"Results of clinical investigation of anti-nicotine drug patches","volume":"3","author":"Ostrovskaia","year":"1994","journal-title":"Meditsinskaia Tekhnika"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/JTO.0b013e318215a4dc","article-title":"A smoking cessation intervention for thoracic surgery and oncology clinics","volume":"6","author":"Park","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0351|cit351","unstructured":"Effects of Chantix on relapse prevention for smoking cessation clinicaltrials.gov\/ct2\/show\/NCT00948649"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.drugalcdep.2009.07.020","article-title":"Working memory deficits predict short-term smoking resumption following brief abstinence","volume":"106","author":"Patterson","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.biopsych.2008.08.028","article-title":"Varenicline improves mood and cognition during smoking abstinence","volume":"65","author":"Patterson","year":"2009","journal-title":"Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/ntr\/ntq049","article-title":"Mouse model predicts effects of smoking and varenicline on event-related potentials in humans","volume":"12","author":"Rudnick","year":"2010","journal-title":"Nicotine & Tobacco Research"},{"issue":"44","key":"10.1002\/14651858.CD006103.pub8-BIB0355|cit355","first-page":"2088","article-title":"Smoking cessation with cytisine 'Tabex' tablets","volume":"23","author":"Paun","year":"1968","journal-title":"Sonderduck Aus Das Deutsche Gesundheitwesen"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0356|cit356","first-page":"15","article-title":"Tabex: registering and treatment of smokers with chronic bronchitis in the consultation against tobacco smoking - Berlin","volume":"3","author":"Paun","year":"1970","journal-title":"Medico-Biologic Information"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/JCP.0000000000001056","article-title":"Efficacy of varenicline in patients with severe alcohol dependence: a pilot double-blind randomized and controlled study","volume":"39","author":"Pfeifer","year":"2019","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0358|cit358","unstructured":"Flexible dosing trial NDA 21-928 [reported in CDER 2006] 2006"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1521-0391.2010.00066.x","article-title":"The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study","volume":"19","author":"Poling","year":"2010","journal-title":"American Journal on Addictions"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12916-014-0172-8","article-title":"Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation","volume":"12","author":"Ramon","year":"2014","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0361|cit361","unstructured":"Concurrent bupropion\/varenicline for smoking cessation (ConNic4) clinicaltrials.gov\/ct2\/show\/NCT01303861"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1176\/appi.ajp.2014.13050595","article-title":"Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm","volume":"171","author":"Rose","year":"2014","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0363|cit363","unstructured":"Rose JE Behm FM Combination varenicline\/bupropion treatment benefits male NRT-nonresponders Society for Research on Nicotine and Tobacco 19th Annual Meeting March 13-16 Boston MA 2013 261"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.addbeh.2014.05.008","article-title":"The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement","volume":"39","author":"Schlienz","year":"2014","journal-title":"Addictive Behaviors"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0365|cit365","first-page":"557","article-title":"Medical support of nicotine withdrawal. Report on a double blind trial in over 5000 smokers (author's transl)","volume":"116","author":"Schmidt","year":"1974","journal-title":"Munch Med Wachr"},{"issue":"8","key":"10.1002\/14651858.CD006103.pub8-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/10410236.2011.566829","article-title":"A novel recruitment message to increase enrollment into a smoking cessation treatment program: preliminary results from a randomized trial","volume":"26","author":"Schnoll","year":"2011","journal-title":"Health Communication"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0367|cit367","first-page":"320","article-title":"Varenicline treatment for smoking cessation in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0369|cit369","doi-asserted-by":"crossref","unstructured":"Sicras-Mainar A Navarro-Artieda R Diaz-Cerezo S Sanz de Burgoa V Effectiveness of varenicline compared with bupropion and nicotine replacement therapy (NRT) for smoking cessation in two smoking specialized units in the primary care setting Society for Research on Nicotine and Tobacco Europe Conference: Bath, UK, 6-9 October 2010","DOI":"10.1016\/S1098-3015(11)72236-7"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0370|cit370","unstructured":"Varenicline for cognitive deficits and cigarette smoking in schizophrenia ClinicalTrials.gov\/ct2\/show\/NCT00802919"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0371|cit371","first-page":"S364","article-title":"Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia","volume":"38","author":"Smith","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1360-0443.2007.02083.x","article-title":"Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness","volume":"103","author":"Stapleton","year":"2008","journal-title":"Addiction"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0373|cit373","first-page":"30","article-title":"On the therapeutic effectiveness and tolerability of Tabex [Bulgarian]","volume":"23","author":"Stoyanov","year":"1972","journal-title":"Savremenna Medicina"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/ntr\/ntr003","article-title":"Adherence to varenicline in the COMPASS smoking cessation intervention trial","volume":"13","author":"Catz","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jsat.2008.09.001","article-title":"Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting","volume":"36","author":"Halperin","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jsat.2010.03.007","article-title":"Smoking outcome by psychiatric history after behavioral and varenicline treatment","volume":"38","author":"McClure","year":"2010","journal-title":"Journal of Substance Abuse and Treatment"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11606-009-0926-8","article-title":"Mood, side-effects and smoking outcomes among persons with and without probably lifetime depression taking varenicline","volume":"24","author":"McClure","year":"2009","journal-title":"Journal of General Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.amepre.2010.01.024","article-title":"Behavioral counseling and varenicline treatment for smoking cessation","volume":"38","author":"Swan","year":"2010","journal-title":"American Journal of Preventive Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/ntr\/ntq257","article-title":"Utilization of services in a randomized trial testing phone- and web-based interventions for smoking cessation","volume":"13","author":"Zbikowski","year":"2011","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-2753.2008.01045.x","article-title":"Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence","volume":"15","author":"Bolin","year":"2009","journal-title":"Journal of Evaluation in Clinical Practice"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1360-0443.2009.02646.x","article-title":"Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment","volume":"104","author":"Hajek","year":"2009","journal-title":"Addiction"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1524-4733.2009.00672.x","article-title":"The cost-effectiveness of an extended course (12 + 12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model","volume":"13","author":"Knight","year":"2010","journal-title":"Value in Health"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"A472","DOI":"10.1016\/S1098-3015(10)65622-7","article-title":"An evaluation of the cost-effectiveness of an extended course of varenicline in preventing smokers who have quit from relapsing [PSM3]","volume":"10","author":"Knight","year":"2007","journal-title":"Value in Health"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1751-7141.2008.00003.x","article-title":"A longer course of varenicline therapy improves smoking cessation rates","volume":"11","author":"Lee","year":"2008","journal-title":"Preventive Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0385|cit385","first-page":"348","article-title":"Varenicline as maintenance therapy","volume":"9","author":"O'Brien","year":"2007","journal-title":"Current Psychiatry Reports"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.296.1.64","article-title":"Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial","volume":"296","author":"Tonstad","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0387|cit387","unstructured":"Varenicline for long-term NRT users clinicaltrials.gov\/ct2\/show\/NCT00977249"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/ntr\/nts146","article-title":"Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial","volume":"15","author":"T\u00f8nnesen","year":"2013","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2011.02.003","article-title":"Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study","volume":"129","author":"Weiner","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0390|cit390","unstructured":"Zatonski W Cedzynska M Przewozniak K Karpinska E Lewandowska D Pstrucha E An open label observational study of herbal cytisine (Tabex) as an aid to smoking cessation [POS1-058] Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic 2005"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/tc.2006.016097","article-title":"An uncontrolled trial of cytisine (Tabex) for smoking cessation","volume":"15","author":"Zatonski","year":"2006","journal-title":"Tobacco Control"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0392|cit392","first-page":"66 [OS205]","article-title":"Efficacy of varenicline, an nicotinic acetylcholine receptor partial agonist, vs placebo for smoking cessation. A randomized controlled trial","volume":"18 Suppl 4","author":"Wiratmoko","year":"2013","journal-title":"Respirology"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD006103.pub8-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"C207","DOI":"10.1016\/j.jacc.2014.06.961","article-title":"Efficacy and safety of varenicline for smoking cessation in patients with CAD undergoing PCI","volume":"64","author":"Yujie","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"e028832","DOI":"10.1136\/bmjopen-2018-028832","article-title":"Randomised, placebo-controlled, double-blind, double-dummy, multicentre trial comparing electronic cigarettes with nicotine to varenicline and to electronic cigarettes without nicotine: the ECSMOKE trial protocol","volume":"9","author":"Berlin","year":"2019","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0395|cit395","unstructured":"Randomized trial of electronic cigarettes with or without nicotine in smoking cessation clinicaltrials.gov\/ct2\/show\/NCT03630614"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"100412","DOI":"10.1016\/j.conctc.2019.100412","article-title":"Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): a protocol for a randomized controlled trial","volume":"15","author":"Caponnetto","year":"2019","journal-title":"Contemporary Clinical Trials Communications"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0397|cit397","unstructured":"Individual tobacco cessation research based on nicotine metabolite ratio in smoking patients with chronic obstructive pulmonary disease: a randomized controlled trial www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR1900021400 2019"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0398|cit398","unstructured":"Effect of varenicline in smoking cessation after invasive treatment of coronary artery disease en.irct.ir\/trial\/49723"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00213-020-05713-7","article-title":"The impact of three weeks of pre-quit varenicline on reinforcing value and craving for cigarettes in a laboratory choice procedure","volume":"238","author":"Lawson","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0400|cit400","unstructured":"EVarQuit: extended pre-quit varenicline to assist in quitting smoking clinicaltrials.gov\/show\/NCT03262662"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0401|cit401","unstructured":"Methadone maintenance treatment and smoking cessation (MMTASC) clinicaltrials.gov\/ct2\/show\/NCT00906386"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0402|cit402","unstructured":"Smoking cessation program in the preadmission clinic: the use of a teachable moment ClinicalTrials.gov\/show\/NCT01243203"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0403|cit403","unstructured":"Smoking cessation study in healthy adolescent smokers clinicaltrials.gov\/ct2\/show\/NCT01312909"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0404|cit404","unstructured":"The Canadian HIV quit smoking trial: tackling the co-morbidities of depression and cardiovascular disease in HIV+ smokers ClinicalTrials.gov\/show\/NCT01800019"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0405|cit405","unstructured":"Early in-hospital initiation of pharmacotherapy for smoking cessation, concomitant with nurse-led support, in patients after an acute coronary syndrome (ACS) ClinicalTrials.gov\/show\/NCT02106637"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0406|cit406","unstructured":"The effects of behavioral counseling plus nicotine replacement therapy (NRT) or varenicline on smoking cessation among smokers high and low in intrinsic reward sensitivity ClinicalTrials.gov\/show\/NCT02162849"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0407|cit407","unstructured":"Behavioral activation and varenicline for smoking cessation in depressed smokers clinicaltrials.gov\/show\/NCT02378714"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0408|cit408","unstructured":"Optimizing smoking cessation for people with HIV\/AIDS who smoke clinicaltrials.gov\/show\/NCT02460900"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0409|cit409","unstructured":"Management of tobacco treatment intervention in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes clinicaltrials.gov\/show\/NCT02856581"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0410|cit410","unstructured":"Combined bio- and neuro- feedback vs. varenicline use for smoking cessation clinicaltrials.gov\/show\/NCT02991781"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0411|cit411","unstructured":"A trial of directly observed and long-term varenicline clinicaltrials.gov\/show\/NCT03365362"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0412|cit412","unstructured":"Varenicline OTC trial on efficacy and safety clinicaltrials.gov\/show\/NCT03557294"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0413|cit413","unstructured":"Novel pharmacotherapy approaches in smokers with serious mental illness clinicaltrials.gov\/show\/NCT04011280"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0414|cit414","unstructured":"Varenicline versus cytisine for smoking cessation in primary care setting clinicaltrials.gov\/show\/NCT04015414"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0415|cit415","unstructured":"Cessation screening project clinicaltrials.gov\/show\/NCT04188873"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0416|cit416","unstructured":"STARS (Smoking Treatment And Remote Sampling) study clinicaltrials.gov\/show\/NCT04525755"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0417|cit417","unstructured":"Nicotine replacement therapy, counseling, varenicline, and bupropion for smoking cessation, the PISCES I trial clinicaltrials.gov\/show\/NCT04604509"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0418|cit418","unstructured":"PeRiopEratiVE smokiNg cessaTion Trial (PREVENT) clinicaltrials.gov\/show\/NCT05102123"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0419|cit419","unstructured":"Cytisine and e-cigarettes with supportive text-messaging for smoking cessation (Cess@Tion) clinicaltrials.gov\/show\/NCT05311085"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0420|cit420","unstructured":"Varenicline versus transdermal nicotine patch for smoking cessation in patients with coronary heart disease clinicaltrials.gov\/ct2\/show\/NCT00959972"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0421|cit421","first-page":"53D","article-title":"Varenicline versus transdermal nicotine patch for smoking cessation in patients with coronary heart disease: a pilot randomized trial","volume":"26 Suppl D","author":"Reid","year":"2010","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0422|cit422","unstructured":"Efficacy and safety of smoking cessation with varenicline tartrate in diabetic smokers: a double-blind, placebo-controlled, randomized trial www.clinicaltrialsregister.eu\/ctr-search\/search?query=2009-017599-26"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0423|cit423","unstructured":"Efficacy and safety of smoking cessation with varenicline tartrate in diabetic smokers (DIASMOKE) clinicaltrials.gov\/ct2\/show\/NCT01387425"},{"issue":"7","key":"10.1002\/14651858.CD006103.pub8-BIB0424|cit424","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s11739-021-02684-1","article-title":"A double blind randomized controlled trial investigating efficacy and safety of varenicline for smoking cessation in patients with type 2 diabetes: study protocol","volume":"16","author":"Russo","year":"2021","journal-title":"Internal & Emergency Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0425|cit425","unstructured":"Efficacy safety and health-related quality of life (HRQoL) of cytisine in smoking cessation www.who.int\/trialsearch\/Trial2.aspx?TrialID=TCTR20180312001"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0426|cit426","unstructured":"Studying partial-agonists for ethanol and tobacco elimination in Russians with HIV (St PETER HIV) clinicaltrials.gov\/show\/NCT02797587"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"100625","DOI":"10.1016\/j.conctc.2020.100625","article-title":"Design of a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, Russia","volume":"19","author":"Tindle","year":"2020","journal-title":"Contemporary Clinical Trials Communications"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0428|cit428","unstructured":"Raw M McNeill A Arnott D Varenicline: guidance for health professionals on a new prescription-only stop smoking medication www.ash.org.uk\/html\/cessation\/ASHVareniclineguidance.pdf"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0429|cit429","unstructured":"Actions on Smoking and Health (ASH) Briefing: Health inequalities and smoking ash.org.uk\/uploads\/ASH-Briefing_Health-Inequalities.pdf 2019"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0430|cit430","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009329.pub2","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","author":"Cahill","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0431|cit431","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":"Varenicline: an alpha4beta2 nAChR nicotinic receptor partial agonist for smoking cessation","volume":"48","author":"Coe","year":"2005","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0432|cit432","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/add.13592.","article-title":"The Food and Drug Administration and varenicline: should risk communication be improved?","volume":"112","author":"Davies","year":"2017","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0433|cit433","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0434|cit434","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004306.pub4","article-title":"Interventions for smokeless tobacco use cessation","author":"Ebbert","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0435|cit435","first-page":"1","article-title":"Cytisine for smoking cessation: a literature review and a meta-analysis","volume":"166","year":"2006","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1360-0443.2007.01822.x","article-title":"The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis","volume":"102","author":"Etter","year":"2007","journal-title":"Addiction"},{"issue":"1-3","key":"10.1002\/14651858.CD006103.pub8-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.drugalcdep.2007.06.017","article-title":"Cytisine for smoking cessation: a research agenda","volume":"92","author":"Etter","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0438|cit438","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11606-021-06915-1","article-title":"Association between conflicts of interest and authors\u2019 positions on harms of varenicline: a cross-sectional analysis","volume":"37","author":"Fabbri","year":"2022","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0439|cit439","unstructured":"FDA issues Public Health Advisory on Chantix www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2008\/ucm116849.htm"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/14728214.9.1.39","article-title":"Advances in pharmacotherapy for tobacco dependence","volume":"9","author":"Foulds","year":"2004","journal-title":"Expert Opinion on Emerging Drugs"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0441|cit441","doi-asserted-by":"publisher","first-page":"105700","DOI":"10.1016\/j.phrs.2021.105700","article-title":"Cytisine and cytisine derivatives. More than smoking cessation aids","volume":"170","author":"Gotti","year":"2021","journal-title":"Pharmacological Research"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0442|cit442","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"7414","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0443|cit443","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/1462220031000070552","article-title":"Measures of abstinence in clinical trials: issues and recommendations","volume":"5","author":"Hughes","year":"2003","journal-title":"Nicotine & Tobacco Research"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1517\/13543780903184591","article-title":"Discontinued psychiatric drugs in 2008","volume":"18","author":"Kirchhoff","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"33","key":"10.1002\/14651858.CD006103.pub8-BIB0446|cit446","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18330","article-title":"What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? a systematic review and economic evaluation","volume":"18","author":"Leaviss","year":"2014","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0447|cit447","doi-asserted-by":"publisher","first-page":"e002849","DOI":"10.1161\/JAHA.115.002849","article-title":"Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"5","author":"Sterling","year":"2016","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0448|cit448","first-page":"e1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS One"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0449|cit449","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015226","article-title":"Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses","author":"Lindson","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0450|cit450","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005231.pub3","article-title":"Interventions to reduce harm from continued tobacco use","author":"Lindson-Hawley","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0451|cit451","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003999.pub5","article-title":"Relapse prevention interventions for smoking cessation","author":"Livingstone-Banks","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0452|cit452","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/add.15769","article-title":"Effects of interventions to combat tobacco addiction: Cochrane update of 2019 and 2020 reviews","volume":"117","author":"Livingstone-Banks","year":"2022","journal-title":"Addiction"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0453|cit453","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015314","article-title":"Interventions for smokeless tobacco use cessation","author":"Livingstone-Banks","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0454|cit454","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/07853890.2012.705016","article-title":"Comparisons of high-dose and combination nicotine replacement therapy, varenicline and bupropion for smoking cessation: a systematic review and multiple-treatment meta-analysis","volume":"44","author":"Mills","year":"2012","journal-title":"Annals of Medicine"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0455|cit455","unstructured":"National Institute for Health and Clinical Excellence Varenicline for smoking cessation www.nice.org.uk\/nicemedia\/pdf\/TA123Guidance.pdf (accessed 14th April 2008) 2007"},{"issue":"6","key":"10.1002\/14651858.CD006103.pub8-BIB0456|cit456","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jama.2022.0395","article-title":"Treatment of tobacco smoking: a review","volume":"327","author":"Rigotti","year":"2022","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0457|cit457","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0458|cit458","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0459|cit459","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14622200410001734067","article-title":"Recommendations for the assessment of tobacco craving and withdrawal in smoking cessation trials","volume":"6","author":"Shiffman","year":"2004","journal-title":"Nicotine & Tobacco Research"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0460|cit460","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000124","article-title":"Lobeline for smoking cessation","author":"Stead","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0461|cit461","doi-asserted-by":"crossref","first-page":"h1109","DOI":"10.1136\/bmj.h1109","article-title":"Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis","volume":"350","author":"Thomas","year":"2015","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0462|cit462","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/add.15675","article-title":"Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials","volume":"117","year":"2020","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0463|cit463","first-page":"777","article-title":"Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy","volume":"58","author":"Tutka","year":"2005","journal-title":"Pharmacological Reports"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0464|cit464","first-page":"33","article-title":"Cytisine - renaissance of well known alkaloid. Pharmacological aspects of efficacy in the treatment of tobacco dependence","volume":"1","author":"Tutka","year":"2006","journal-title":"Farmakoterapia w Psychiatrii i Neurologii"},{"issue":"10","key":"10.1002\/14651858.CD006103.pub8-BIB0465|cit465","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/13543784.17.10.1473","article-title":"Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation","volume":"17","author":"Tutka","year":"2008","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"11","key":"10.1002\/14651858.CD006103.pub8-BIB0466|cit466","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/add.14721","article-title":"Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation","volume":"114","author":"Tutka","year":"2019","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0467|cit467","volume-title":"Smoking cessation: a report of the Surgeon General","author":"US Department of Health and Human Services","year":"2020"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0468|cit468","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1360-0443.2010.03282.x","article-title":"Australia's experience with varenicline: usage, costs and adverse reactions [letter]","volume":"106","author":"Walsh","year":"2011","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0469|cit469","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1360-0443.2004.00995.x","article-title":"Outcome criteria in smoking cessation trials: proposal for a common standard","volume":"100","author":"West","year":"2005","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0470|cit470","unstructured":"World Health Organization Two new tobacco cessation medicines added to the WHO essential medicines list www.who.int\/news\/item\/05-11-2021-two-new-tobacco-cessation-medicines-added-to-the-who-essential-medicines-list"},{"key":"10.1002\/14651858.CD006103.pub8-BIB0471|cit471","unstructured":"World Health Organization World Health Organization fact sheets: Tobacco www.who.int\/en\/news-room\/fact-sheets\/detail\/tobacco"},{"issue":"1","key":"10.1002\/14651858.CD006103.pub8-BIB0472|cit472","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub2","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0473|cit473","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub3","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006103.pub8-BIB0474|cit474","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub5","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006103.pub8-BIB0475|cit475","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub6","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006103.pub8-BIB0476|cit476","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub7","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006103.pub8-BIB0477|cit477","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Hey","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006103.pub9","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T17:52:49Z","timestamp":1686505969000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006103.pub8"}},"subtitle":[],"editor":[{"name":"Cochrane Tobacco Addiction Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":477,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006103.pub8","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]}}}